Organovo to Present Data on FXR314 at Digestive Diseases Week (DDW2024)
Organovo, a clinical-stage biotechnology company (Nasdaq: ONVO), announces its presentation at Digestive Diseases Week (DDW2024) in Washington, D.C., from May 18-21, 2024. The company will present data on its lead drug, FXR314, a combination therapy with tofacitinib for inflammatory bowel disease (IBD) and ulcerative colitis. The poster titled 'Combination therapy of the FXR agonist FXR314 with tofacitinib in models of inflammatory bowel disease' will be showcased on May 18, 2024, at 12:30 EDT. This event is a significant opportunity for Organovo to engage with prescribers and potential partners.
- Presenting at DDW2024 provides significant exposure to a large gathering of gastrointestinal physicians.
- Presentation of combination therapy data may increase the attractiveness of FXR314 for potential partnerships.
- The inclusion of tofacitinib in combination therapy may enhance the drug's efficacy in treating IBD and ulcerative colitis.
- No clinical efficacy or safety data has been disclosed in the press release.
- There is no new financial or business development information provided.
- Potential delays in drug development or partnership finalization are not addressed.
Renowned gastrointestinal diseases conference to held in Washington, D.C. May 18-21, 2024
SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) including ulcerative colitis, today announces it will be presenting data on the Company’s lead clinical-stage drug, FXR314 during DDW2024, which is being held in Washington, D.C. May 18-21, 2024.
The poster, titled, “Combination therapy of the FXR agonist FXR314 with tofacitinib in models of inflammatory bowel disease,” will be presented on Saturday May 18, 2024 at 12:30 EDT in the session “Translational application of intestinal stem cells and organoid models.”
“We look forward to connecting with prescribers and potential partners during DDW2024, which is one of the largest gatherings of gastrointestinal physicians in the United States. We look forward to sharing our first set of findings on the combination therapy potential of FXR314, which, complementing its monotherapy promise, adds to its attractiveness for partnering,” stated Keith Murphy, Organovo’s Executive Chairman.
About Organovo
Organovo is a clinical stage biotechnology company that is developing drugs that are demonstrated to be effective in three-dimensional (3D) human tissues as candidates for drug development. The company’s lead molecule, FXR314, is on the path for Phase 2 investigation in inflammatory bowel disease and has potential application in metabolic liver disease and oncology. The company has proprietary technology used to build 3D human tissues that mimic key aspects of native human tissue composition, architecture, function, and disease. For more information visit Organovo's website at www.organovo.com.
Forward Looking Statements
Any statements contained in this press release that do not describe historical facts constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. These risks and uncertainties and other factors are identified and described in more detail in the Company’s filings with the SEC, including its Annual Report on Form 10-K filed with the SEC on July 14, 2023, as such risk factors are updated in its most recently filed Quarterly Report on Form 10-Q filed with the SEC on February 8, 2024 and the Registration Statement on Form S-1 (File No. 333-278668), as amended. You should not place undue reliance on these forward-looking statements, which speak only as of the date that they were made. These cautionary statements should be considered with any written or oral forward-looking statements that the Company may issue in the future. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to reflect actual results, later events, or circumstances or to reflect the occurrence of unanticipated events.
Contact
CORE IR
pr@coreir.com
Source: Organovo, Inc.
FAQ
What drug will Organovo present at DDW2024?
When and where is DDW2024 being held?
What is the focus of Organovo's presentation at DDW2024?
When will Organovo present its data at DDW2024?
